Breaking News
December 14, 2017 - These annual checkups help seniors not only survive but thrive
December 14, 2017 - Study reveals impact of diabetes during pregnancy on baby’s heart
December 14, 2017 - Huntington’s disease drug clears initial hurdles
December 14, 2017 - TPU researchers create 3D-printed models of children’s hearts
December 14, 2017 - Brain responses of children with inherited dyslexia risk predict their future reading speed
December 14, 2017 - Study: New Furosemide Formulation Simplifies Administration for HF
December 14, 2017 - Discrimination harms your health—and your partner’s
December 14, 2017 - Having older brothers may increase the likelihood of being gay
December 14, 2017 - New scientific yardstick released to help early detection of Alzheimer’s disease
December 14, 2017 - New finding demonstrates what happens at cellular level during onset of type2 diabetes
December 14, 2017 - Study identifies potassium as key to circadian rhythms in red blood cells
December 14, 2017 - NIH expected to award up to $70 million to launch Alzheimer’s Clinical Trials Consortium
December 14, 2017 - Pitting pathogens against each other could prevent drug resistance emerging
December 14, 2017 - Study provides new insights into development of Sonic Hedgehog medulloblastoma
December 14, 2017 - Dr. Reddy’s Announces Approval of Impoyz (clobetasol propionate) Cream for Plaque Psoriasis
December 14, 2017 - Gene Screens Can Alter Perception, Behavior
December 14, 2017 - Can Scrotal Vein Condition Hike Heart Risks?: MedlinePlus Health News
December 14, 2017 - Molecules in spit may be able to diagnose and predict length of concussions
December 14, 2017 - Children’s Colorado and RxRevu partner to help prescribers better meet needs of pediatric patients
December 14, 2017 - Researchers discover new way to attack drug-resistant prostate cancer cells
December 14, 2017 - Scientists develop new, high resolution method for identifying microbial species and strains
December 14, 2017 - Declining trend of salmonellosis cases has leveled off in the EU
December 14, 2017 - Death receptors in the blood can help measure risk of cardiovascular diseases, type 2 diabetes
December 14, 2017 - How to Perk Up the Holidays for Hospital Patients
December 14, 2017 - Prolonged Sedation May be Bad for Baby’s Brain
December 14, 2017 - The pediatric submersion score predicts children at low risk for injury following submersions
December 14, 2017 - Video game helps doctors to quickly recognize trauma patients who need high levels of care
December 14, 2017 - Younger persons newly-diagnosed with type 2 diabetes have poorer health than older patients
December 14, 2017 - Clinician re-examines evidence on re-use of catheters and UTIs in people with spinal cord injuries
December 14, 2017 - UK and Russian researchers join forces against AMR
December 14, 2017 - Results of Bariatric Surgery Hold Up Over Time
December 14, 2017 - High-intensity exercise delays Parkinson’s progression
December 14, 2017 - Protein structure could pave way for effective drugs to treat cystic fibrosis
December 14, 2017 - Minority people less likely to see dermatologist for psoriasis treatment
December 14, 2017 - Study indicates decline in use of chemotherapy for early stage breast cancer patients
December 14, 2017 - Chagas disease presents real public health problem to Canadians
December 14, 2017 - Experts call for rigorous clinical trials in use of experimental fetal therapy
December 14, 2017 - Lactic acid bacteria can offer protection against subtypes of influenza A virus
December 14, 2017 - Tapeworm drug could provide new hope for patients with Parkinson’s disease
December 14, 2017 - Parkinson’s progression delayed through high-intensity exercise, study says
December 14, 2017 - Researchers discover potential regulator essential for killer T cells to reside in tumors
December 14, 2017 - Tailor-made protein combats several kinds of pathogenic bacteria
December 14, 2017 - Hidden genes hold blueprints for designing new anti-cancer drugs
December 14, 2017 - Male virgins still at risk for acquiring HPV, study finds
December 14, 2017 - Study reveals novel molecular targets to improve chemotherapy’s efficiency against leukemia
December 14, 2017 - Talazoparib Significantly Extends Progression-Free Survival in Phase 3 EMBRACA Trial of Patients with Metastatic Breast Cancer
December 14, 2017 - AHA: Hospital QI Initiative Fails to Budge Outcomes in India
December 14, 2017 - Scientists observe tremors associated with Parkinson’s disease in fruit flies
December 14, 2017 - Newly discovered molecular chaperones may soon be part of therapies for Huntington’s disease
December 14, 2017 - Performing surgery on virtual patient could provide valuable insight into consequences
December 13, 2017 - New insights into mosquito sex protein could provide strategies to control diseases
December 13, 2017 - Lilly’s Taltz (ixekizumab) Receives U.S. FDA Approval for the Treatment of Active Psoriatic Arthritis
December 13, 2017 - Step Into Sunshine | Medpage Today
December 13, 2017 - Poor Prognosis for Diabetic Foot Sores: MedlinePlus Health News
December 13, 2017 - Exercise alone does not lead to weight loss in women—in the medium term
December 13, 2017 - Researchers use new approach to identify casual mechanisms in depression
December 13, 2017 - Genetic Analysis and Bio-Rad enter into supply and distribution agreement for GA-map clinical test
December 13, 2017 - Study finds barriers to stem cell transplant use among multiple myeloma patients from minority groups
December 13, 2017 - Scientists discover how axons in developing visual system stabilize their connections
December 13, 2017 - Novel compound inhibits mycomembrane biosynthesis and kills tuberculosis bacteria
December 13, 2017 - FDA Launches New Tool for Sharing Information That Allows Doctors to Better Manage Antibiotic Use
December 13, 2017 - Evolocumab Wins FDA Approval for Stand-Alone CVD Prevention
December 13, 2017 - Powerful Clot-Busting Drugs Not Useful After Leg Blockages: Study: MedlinePlus Health News
December 13, 2017 - The fight against obesity: To tax or not to tax?
December 13, 2017 - Isolation during holidays can impact health of seniors
December 13, 2017 - Specialized physiotherapy provides many benefits for patients with Parkinson’s disease
December 13, 2017 - Pairing immunotherapy drug with chemotherapy proves beneficial for relapsed acute myeloid leukemia
December 13, 2017 - Researchers find link between brain structure and hallucination proneness, musical aptitude
December 13, 2017 - Radiation responsive molecules derived from horse chestnuts aid cancer imaging
December 13, 2017 - New Gene Therapy May Be Cure for ‘Bubble Boy’ Disease
December 13, 2017 - MorningBreak: Insurance Driving Drug Prices? Crunch Time for ACA; The ‘Other’ Drug Problem
December 13, 2017 - Are Stents Really Useless After Chest Pain? Cardiologists Not Sure: MedlinePlus Health News
December 13, 2017 - Can you train yourself to develop ‘super senses’?
December 13, 2017 - Cellular self-digestion process plays role in development of autoimmune diseases
December 13, 2017 - E-cigarette use among youth leads to smoking as adults finds study
December 13, 2017 - New nanomaterial could enable new types of chemical processes in pharma, materials and chemical industries
December 13, 2017 - Another CGRP Drug Gains Ground in Migraine
December 13, 2017 - Trigger for most common form of vision loss discovered
December 13, 2017 - Study reveals link between estrogen and infertility
December 13, 2017 - Researchers suggest role for MKL1 protein in development of inflammatory bowel disease
New treatment aims to target abnormally shaped protein in deadly childhood brain cancer

New treatment aims to target abnormally shaped protein in deadly childhood brain cancer

image_pdfDownload PDFimage_print

Children with an extremely deadly form of brain cancer might benefit from a new treatment that aims to direct an immune response against an abnormally shaped protein found exclusively on cancer cells, according to a new study led by UC San Francisco researchers.

The focus of the study, published online December 4, 2017 in the Journal of Experimental Medicine, is diffuse intrinsic pontine glioma (DIPG), an aggressive pediatric brain cancer. DIPG is rare — estimates suggest that about 300 new cases occur in the United States each year — but almost always fatal.

Because DIPG occurs in a difficult-to-access area of the brain stem that controls vital functions such as breathing, blood pressure, and heart rate, these tumors are almost impossible to remove surgically. Radiation therapy is the current standard treatment, but is rarely effective for long, according to Hideho Okada, MD, PhD, professor of neurological surgery and director of the Brain Tumor Immunotherapy Center at UCSF, and the senior author of the study.

“It is important to develop more innovative treatment approaches for childhood brain cancers, which now are the leading cause of cancer death in children. DIPG is a very deadly type of brain cancer, and not many children survive beyond 12 months from the time of diagnosis.” said Okada, also a member of the Helen Diller Family Comprehensive Cancer Center (HDFCC) at UCSF and of the Parker Institute for Cancer Immunotherapy.

Okada, along with Sabine Mueller, MD, PhD, MAS, an assistant professor of clinical neurology at UCSF and a HDFCCC member, already are leading a phase I clinical trial in children with DIPG and closely related gliomas, in order to evaluate a new anti-tumor vaccine based on the new target identified by Okada’s research group.

The new study’s preclinical results also support the development of an immunotherapy treatment that is potentially more powerful than a simple vaccine, one in which some of the patient’s own immune cells would be genetically engineered to recognize the molecular target, which is found on tumor cells in most cases of DIPG and related gliomas, but not on normal cells.

The immune system needs a boost to fight established tumors. Normally it can distinguish a healthy cell from a cell infected by invading pathogens by inspecting bits of molecules, called antigens, which cells display on their outer surface. Very early in life the immune system learns to tolerate rather than to attack cells displaying antigens made by the body’s own cells. Because tumors arise from our own cells, the immune system is likely to tolerate rather than attack the cells of an established tumor.

The target of the new DIPG treatment is a “neoantigen.” A neoantigen is a fragment of a protein made by a cancer cell that has an abnormal structure — and often an abnormal function — due to genetic mutation, a hallmark of cancer. Researchers are developing techniques to select neoantigens that they think will be the most likely to be seen and identified as foreign by the immune system, and they aim to develop immunotherapies to boost immune responses to tumor cells displaying these neoantigens.

Tumors often have a large variety of mutated proteins, but many of these proteins are too similar to normal antigens for the immune system to recognize them as a threat. Even if the immune system can be coaxed to attack cells displaying a fragment of these mutant proteins, it might also learn to attack healthy cells displaying the protein’s normal counterpart. In fact, autoimmunity is a risk for many patients given current immunotherapies, such as “checkpoint inhibitors,” which release the brakes that prevent the immune system from attacking tumor cells.

The hope is that well-chosen neoantigens can be used to develop treatments that will more selectively and potently target tumors. Neoantigen-based treatments are still experimental, but many are in clinical trials.

The neoantigen Okada and colleagues worked with is a fragment of a protein called histone 3 variant 3. This protein is identically mutated in about 70 percent of cases of DIPG and results in abnormal control of gene activity in tumor cells. Earlier studies by other researchers found that when the mutation is present, it is present in all, or nearly all cells of the tumor.

“This may be an ideal case of a tumor neoantigen,” Okada, said. “Most neoantigens in cancer are unique to individual patients, but this is one of very, very few examples of a shared, common neoantigen that may have the potential to be used in many patients.”

The researchers used some of the latest computational techniques to predict that a specific fragment of the protein that includes the neoantigen would bind especially strongly to a protein called HLA A, which displays antigens for inspection by patrolling immune cells called T cells. The strength of this attachment ought to correspond to the likelihood that a neoantigen will be recognized as a threat by the immune system.

In laboratory experiments the researchers confirmed this prediction. They found a strong affinity between the tumor neoantigen and a type of HLA A found in about 40 percent of DIPG patients. In contrast, they found no corresponding affinity between this HLA A type and non-mutated antigens from related proteins produced by healthy cells, suggesting that treatments based on this neoantigen should be specific to tumor cells only.

The goal of the neoantigen-containing vaccine now being tested in Okada and Mueller’s clinical trial is to train the immune system’s T cells to recognize the neoantigen in the vaccine, which should then trigger an immune response to tumor cells in the brain that display the same neoantigen, Okada said.

The new paper also demonstrates a promising, even more powerful form of treatment based on directly engineering patients’ T cells to recognize the target neoantigen. Every T cell has a particular type of T cell receptor protein that can recognize a single antigen paired with an HLA protein. The scientists used T cells from patients with the HLA A type that bound tightly to the novel DIPG neoantigen to identify naturally arising T cell receptors that recognize the combination. They selected the best T cell receptor, cloned it into other T cells, and grew large numbers of these cells in the lab. They then demonstrated that these lab-grown T cells could effectively kill human glioma tumors grown in mice.

“We saw a significant reduction in tumor progression compared to control groups,” said tumor immunologist Zinal Chheda, PhD, a postdoctoral fellow with Okada’s lab and the co-lead author of the study. “The T cell receptor we selected for cloning has an affinity for the neoantigen that is in the range of what we see for antigens from viruses — orders of magnitude greater than what we generally see with neoantigens found on cancer cells.”

Source:

https://www.ucsf.edu/news/2017/12/409181/new-immunotherapy-targets-misshapen-protein-rare-childhood-brain-cancer

Tagged with:

About author

Related Articles